Carroll Financial Associates’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
$29K Sell
175
-1
-0.6% -$152 ﹤0.01% 863
2021
Q3
$25K Buy
176
+13
+8% +$1.9K ﹤0.01% 939
2021
Q2
$21K Buy
163
+4
+3% +$524 ﹤0.01% 1069
2021
Q1
$20K Buy
159
+4
+3% +$493 ﹤0.01% 1011
2020
Q4
$18K Sell
155
-29
-16% -$3.54K ﹤0.01% 947
2020
Q3
$21K Hold
184
﹤0.01% 844
2020
Q2
$20K Sell
184
-16
-8% -$1.7K ﹤0.01% 851
2020
Q1
$16K Hold
200
﹤0.01% 827
2019
Q4
$21K Hold
200
﹤0.01% 862
2019
Q3
$21K Hold
200
﹤0.01% 811
2019
Q2
$20K Sell
200
-2
-1% -$192 ﹤0.01% 826
2019
Q1
$18K Sell
202
-23
-10% -$1.99K ﹤0.01% 781
2018
Q4
$18K Sell
225
-90
-29% -$8.44K ﹤0.01% 696
2018
Q3
$33K Buy
315
+18
+6% +$1.97K ﹤0.01% 590
2018
Q2
$32K Hold
297
﹤0.01% 572
2018
Q1
$29K Sell
297
-19
-6% -$1.95K ﹤0.01% 586
2017
Q4
$31K Buy
316
+47
+17% +$4.46K ﹤0.01% 566
2017
Q3
$24K Sell
269
-10
-4% -$1.06K ﹤0.01% 612
2017
Q2
$31K Hold
279
﹤0.01% 587
2017
Q1
$27K Hold
279
﹤0.01% 598
2016
Q4
$25K Hold
279
﹤0.01% 590
2016
Q3
$23K Sell
279
-1
-0.4% -$84 ﹤0.01% 617
2016
Q2
$22K Sell
280
-14
-5% -$1.07K ﹤0.01% 595
2016
Q1
$21K Hold
294
﹤0.01% 597
2015
Q4
$20K Buy
294
+61
+26% +$4.1K ﹤0.01% 579
2015
Q3
$15K Sell
233
-15
-6% -$1.05K ﹤0.01% 625
2015
Q2
$18K Buy
248
+48
+24% +$3.54K ﹤0.01% 582
2015
Q1
$15K Sell
200
-300
-60% -$21.5K 0.01% 465
2014
Q4
$36K Buy
+500
New +$31.6K 0.02% 283

Other funds holding DGX

Carroll Financial Associates's DGX Position: Q4 2021 in Review

Carroll Financial Associates reduced its Quest Diagnostics (DGX) stake by 0.57% in Q4 2021, selling an estimated $152 and leaving 175 shares worth $29K. The position accounts for ﹤0.01% of the portfolio, ranked #863.

Carroll Financial Associates first reported a position in DGX in Q4 2014 and has held it in 29 quarters since. The position peaked at $36K in Q4 2014. 906 funds tracked by Wall St. Rank hold DGX as of Q4 2021.

  • Carroll Financial Associates held 175 shares of Quest Diagnostics worth $29K as of Q4 2021.
  • Carroll Financial Associates sold 1 Quest Diagnostics share in Q4 2021, an estimated $152.
  • Quest Diagnostics made up ﹤0.01% of Carroll Financial Associates's portfolio in Q4 2021, its #863 holding.
  • Carroll Financial Associates first reported a position in Quest Diagnostics in Q4 2014 and has held it in 29 quarters since.
  • Carroll Financial Associates's Quest Diagnostics position peaked at $36K in Q4 2014.
  • 906 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2021.

Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.